|
Home | Medical-Newswire.Com:
|
(EMAILWIRE.COM, October 29, 2007 ) New York,NY -- CCM Research analyst, Mohammad Sharifzadeh, Ph.D., CFA, has written an update report on Starpharma Holdings Ltd. Starpharma Holdings, Ltd. (SPHRY: OTCQX) (SPL: ASX) is an Australian-based company engaged in the development and application of dendrimer nanotechnologies as drugs and in other life science applications. Starpharma’s business strategy is to use dendrimer-based nanotechnology to discover, develop and commercialize pharmaceuticals for serious human diseases and in life sciences.In the report the analyst states “with the increasing global awareness of the HIV/AIDS problem and the accelerating endeavors at the international, governmental, civil social groups, and even individuals’ levels to prevent and treat this devastating epidemic as quick as possible, Starpharma’s VivaGel stands at the forefront of the global HIV/AIDS prevention strategies.”The analyst continues “we agree with Starpharma’s management that acquisition of DNT results in valuable synergies including more U.S. presence, extensive IP portfolio, road to commercialization, and a more diversified product base.”Regarding Starpharma’s external financing the analyst notes, “They have a strong cash position which can support their operating and R&D expenses should there be a shortfall in revenues. Starpharma has almost a debt free balance sheet with substantial equity which provides the company with the opportunity of external financing should the need arises.”A free copy of the report can be found at www.ccmopportunitybase.com. CCM Research, a division of Cronus Capital Markets, Inc. subscribes to the “Standards for Independent Research Providers” and the principles contained in the Analyst/Corporate Issuer Guidelines jointly promulgated by the CFA Institute and the National Investor Relations Institute, described at: http://www.cfainstitute.org and http://www.niri.org. Cronus Capital Markets, Inc., through its CCM Consulting Division, entered into a one year $30,000.00 contract with the company to assist it with the creation and execution of information-based strategies to overcome market inefficiencies that are commonplace for the vast majority of public companies, including share illiquidity and stagnant market capitalization.Cronus Capital Markets (CCM) is a global investment information firm who strategically produces and introduces, through various forms of analytics and worldwide distribution, information on equity market opportunities. CCM’s equity indexes receive international attention and represent important new benchmarks of growth.SOURCE: Cronus Capital MarketsDianne RudderhamProgram DirectorT: 416-368-3700 ext 223E: Rudderham@cronuscapitalmarkets.com
Dianne Rudderham
rudderham@cronuscapitalmarkets.com 
Source: EmailWire.com
|
|
|
|
